Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Overall, NAD+ Injection is considered compatible with most other therapies, with no known adverse drug interactions, but comprehensive disclosure of ones medication regimen to the treating provider is important for safe care
The quality is guaranteed
For complete thymosin beta-4, intravenous single doses of up to 1260 mg were well tolerated in healthy subjects, with no dose-limiting toxicity Ruff et al., 2010, and recombinant thymosin beta-4 showed no accumulation Wang et al., 2021
No regulatory body Health Canada, the FDA, the EMA, the TGA, or any equivalent has approved BPC-157 as a drug for human or veterinary use
We understand that researchers need high quality compounds to ensure the accuracy and reproducibility of their experiments
